Saint-Gobain has entered into an agreement with Argos Therapeutics to design, integrate and scale production of a range of plastic disposables for use in the automated manufacturing of Argos’ lead product candidate, AGS-003. AGS-003 is currently being tested in a phase III clinical trial for the treatment of metastatic renal cell carcinoma (mRCC).
“We believe Saint-Gobain is the ideal partner to provide us with disposables that meet the technical specifications we need in the manufacturing of our personalized immunotherapies,” says Jeff Abbey, president and CEO of Argos. “Their commitment to this development program and to Argos is a critical step in our effort to bring together all of the high quality resources and expertise we need to support the potential future commercialization of AGS-003. The utilization of their disposables with our automated production technology positions us to maximize throughput while processing biomaterials from multiple patients simultaneously in the same automated manufacturing suite.”
“Argos’ Arcelis® technology platform shows clear potential to support development of a range of autologous cell therapies that could change the future of patient care in cancer and infectious diseases. We are excited about the opportunity to partner with the Argos team to develop and supply the essential range of disposables that will be required to advance AGS-003 through late stage development and on to commercialization” says Steve Maddox, General Manager of Saint-Gobain Performance Plastics’ Life Sciences business unit. We believe our capabilities in design, component manufacturing and custom fluid transfer assemblies, as well as testing and validation, are ideally suited to this cell therapy manufacturing automation project.”